Royal Bank of Canada
SLXN

Royal Bank of Canada’s Silexion Therapeutics SLXN Stock Holding History

Royal Bank of Canada’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+76
New +$459 ﹤0.01% 7921

Other funds holding SLXN

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.37B AUM 28.86% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Royal Bank of Canada's SLXN Position: Q2 2026 in Review

Royal Bank of Canada opened a new position in Silexion Therapeutics (SLXN) in Q2 2026: 76 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #7921 among its holdings.

6 funds tracked by Wall St. Rank hold SLXN as of Q2 2026.

  • Royal Bank of Canada held 76 shares of Silexion Therapeutics worth $0 as of Q2 2026.
  • Silexion Therapeutics was a new Royal Bank of Canada position in Q2 2026.
  • Silexion Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7921 holding.
  • 6 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.